EU medicines agency recommends new cancer and rare disease therapies
The European Medicines Agency (EMA) has recommended approval of several new treatments, including three cancer therapies against aggressive forms of the disease. The Committee for Medicinal Products for Human Use supported, among others, Tarlatamab (Imdylltra), a new immunotherapy for advanced small cell lung cancer.